Adma Biologics (ADMA) Misses Q2 EPS by 8c

Adma Biologics (NASDAQ: ADMA) reported Q2 EPS of ($0.44), $0.08 worse than the analyst estimate of ($0.36). Revenue for the quarter came in at $1.3 million, versus $1.5 million reported last year.

For earnings history and earnings-related data on Adma Biologics (ADMA) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• Credo Technology shares rise on analyst support and conference comments
• HP Inc. projects mid-single-digit PC market decline in 2027